{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:42:49Z","timestamp":1789764169956,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019827","name":"Atrium Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ymthe.2023.10.022","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T22:26:59Z","timestamp":1698877619000},"page":"3478-3489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8168-7132","authenticated-orcid":false,"given":"Marcela P.","family":"Cataldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Vannoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Blaeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raegan","family":"Rawls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessalyn","family":"Killilee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly C.","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi Long","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.10.022_bib1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/glycob\/cwv021","article-title":"Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane","volume":"25","author":"Yoshida-Moriguchi","year":"2015","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymthe.2023.10.022_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11534","article-title":"ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto alpha-dystroglycan","volume":"7","author":"Gerin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.10.022_bib3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.celrep.2016.02.017","article-title":"Identification of a Post-translational Modification with Ribitol-Phosphate and Its Defect in Muscular Dystrophy","volume":"14","author":"Kanagawa","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2023.10.022_bib4","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1086\/324412","article-title":"Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan","volume":"69","author":"Brockington","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2023.10.022_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature00837","article-title":"Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies","volume":"418","author":"Michele","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.10.022_bib6","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/mt.2013.156","article-title":"Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of alpha-dystroglycan and improves muscle functions","volume":"21","author":"Xu","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.10.022_bib7","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1038\/mt.2014.141","article-title":"Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery","volume":"22","author":"Qiao","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.10.022_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omtm.2017.02.002","article-title":"Efficacy of Gene Therapy Is Dependent on Disease Progression in Dystrophic Mice with Mutations in the FKRP Gene","volume":"5","author":"Vannoy","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2023.10.022_bib9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.omtm.2018.10.004","article-title":"Dose-Dependent Effects of FKRP Gene-Replacement Therapy on Functional Rescue and Longevity in Dystrophic Mice","volume":"11","author":"Vannoy","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2023.10.022_bib10","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1038\/s41467-018-05990-z","article-title":"Ribitol restores functionally glycosylated alpha-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice","volume":"9","author":"Cataldi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.10.022_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278482","article-title":"Ribitol dose-dependently enhances matriglycan expression and improves muscle function with prolonged life span in limb girdle muscular dystrophy 2I mouse model","volume":"17","author":"Wu","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2023.10.022_bib12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.10.022_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.omtn.2018.02.008","article-title":"Overexpression of Mutant FKRP Restores Functional Glycosylation and Improves Dystrophic Phenotype in FKRP Mutant Mice","volume":"11","author":"Tucker","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2023.10.022_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbadis.2009.10.016","article-title":"Mutations alter secretion of fukutin-related protein","volume":"1802","author":"Lu","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2023.10.022_bib15","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/hmg\/3.10.1725","article-title":"Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform","volume":"3","author":"Rafael","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2023.10.022_bib16","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/hmg\/4.8.1251","article-title":"Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice","volume":"4","author":"Phelps","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2023.10.022_bib17","doi-asserted-by":"crossref","first-page":"9779","DOI":"10.1038\/s41598-021-89208-1","article-title":"Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model","volume":"11","author":"Marchal","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2023.10.022_bib18","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.nmd.2007.07.005","article-title":"Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human","volume":"17","author":"Neri","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2023.10.022_bib19","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2023.10.022_bib20","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1093\/hmg\/ddq314","article-title":"Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies","volume":"19","author":"Chan","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2023.10.022_bib21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00439-013-1302-7","article-title":"Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes","volume":"132","author":"Blaeser","year":"2013","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymthe.2023.10.022_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/hmg\/ddi026","article-title":"Fukutin-related protein mutations that cause congenital muscular dystrophy result in ER-retention of the mutant protein in cultured cells","volume":"14","author":"Esapa","year":"2005","journal-title":"Hum. Mol. Genet."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623005993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623005993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:09:14Z","timestamp":1761502154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001623005993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1525001623005993"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.10.022","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}